| Jul 9 |
Pulse Biosciences receives breakthrough device status for CellFX system
|
| Jul 8 |
Pulse stock rallies 22% on FDA breakthrough designation
|
| Jul 8 |
Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation
|
| Jul 3 |
Pulse Biosciences, Inc. Announces the Closing of its Rights Offering
|
| Jun 28 |
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
|
| Jun 21 |
A US$60m drop in the market cap of Pulse Biosciences, Inc. (NASDAQ:PLSE) is not what insiders like to see after purchasing shares recently
|
| May 25 |
President & CEO of Pulse Biosciences Burke Barrett Buys More Stock
|
| May 20 |
Pulse Biosciences announces updated timing of rights offering for up to $60M
|
| May 20 |
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
|
